Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB3 | P54284 | 4/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1880872 | 1.00 | CACNB3 (0.42) | CACNB3CACNA2D1CACNA1C | |
| SCHEMBL15225426 | 0.92 | CACNB3 (0.41) | CACNB3CACNA2D1CACNA1C | |
| SCHEMBL1888894 | 0.92 | CACNB3 (0.41) | CACNB3CACNA2D1CACNA1C | |
| SCHEMBL15225424 | 0.92 | CACNB3 (0.41) | CACNB3CACNA2D1CACNA1C | |
| SCHEMBL1888895 | 0.92 | CACNB3 (0.41) | CACNB3CACNA2D1CACNA1C | |
| Mirogabalin SCHEMBL1814663 | 0.89 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1C | |
| Mirogabalin SCHEMBL18051438 | 0.89 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1C | |
| Mirogabalin SCHEMBL1888046 | 0.89 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1C | |
| Mirogabalin SCHEMBL1814664 | 0.89 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1C | |
| Mirogabalin SCHEMBL1888044 | 0.89 | CACNB3 (0.52) | CACNB3CACNA2D1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | claimed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | claimed |
| EP-2657219-A1 | Intermediate for producing bicyclic y-amino acid derivative | Daiichi Sankyo Company, Limited (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-2192109-B1 | BICYCLIC -AMINO ACID DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-7947738-B2 | Bicyclic γ-amino acid derivative | DAIICHI SANKYO COMPANY, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2192109-A1 | BICYCLIC -AMINO ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249229-A1 | BICYCLIC gamma-AMINO ACID DERIVATIVE | GLRA2, GLRB, BCAT1 | CACNB3 1650/4885CACNA2D1 1728/4885CACNA1C 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.